Trial Profile
Efficacy and Safety Evaluation of the New Association on Fixed Dose of Candesartan + Chlorthalidone, Produced by EMS S.A,in Arterial Hypertension Control
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase III
Latest Information Update: 24 Jan 2017
Price :
$35
*
At a glance
- Drugs Candesartan cilexetil/chlortalidone (Primary) ; Losartan/hydrochlorothiazide
- Indications Essential hypertension
- Focus Therapeutic Use
- Sponsors EMS
- 17 Jan 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 22 Jul 2016 Planned End Date changed from 1 Dec 2016 to 1 Aug 2017.
- 22 Jul 2016 Planned primary completion date changed from 1 Oct 2016 to 1 May 2017.